X T L Biopharmaceuticals Ltd
Change company Symbol lookup
Select an option...
XTLB X T L Biopharmaceuticals Ltd
RBLX Roblox Corp
JMIA Jumia Technologies AG
MYDX MyDx Inc
WHF WhiteHorse Finance Inc
INDB Independent Bank Corp (Massachusetts)
SNOW Snowflake Inc.
FAUDX Strategic Advisers® Short Duration Fund
FFBC First Financial Bancorp
SMEBF Sime Darby Bhd
Go

Health Care : Biotechnology | Small Cap Value
Based in Israel
Company profile

XTL Biopharmaceuticals Ltd., incorporated on March 9, 1993, is a biopharmaceutical company. The Company is engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company’s developed drug candidate is hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). Its hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. Its rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$4.45
Day's Change
0.30 (7.23%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.69
Day's Low
4.00
Volume
(Heavy Day)
Volume:
3,989,602

10-day average volume:
377,732
3,989,602

Peloton Deadline Alert

7:21 pm ET June 12, 2021 (Newsfile) Print

New York, New York--(Newsfile Corp. - June 12, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Peloton Interactive Inc. ("Peloton" or the "Company") (NASDAQ: PTON) and reminds investors of the June 28, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $50,000 investing in Peloton stock or options between September 11, 2020 and May 5, 2021 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/PTON.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6455/87381_d4481ab1645e4b3e_001.jpg

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Delaware, Pennsylvania, California and Georgia.

As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) in addition to the tragic death of a child, Peloton's Tread+ had caused a serious safety threat to children and pets as there were multiple incidents of injury to both; (2) safety was not a priority to Peloton as Defendants were aware of serious injuries and death resulting from the Tread+ yet did not recall or suggest a halt of the use of the Tread+; (3) as a result of the safety concerns, the U.S. Consumer Product Safety Commission ("CPSC") declared the Tread+ posed a serious risk to public health and safety resulting in its urgent recommendation for consumers with small children to cease using the Tread+; (4) the CPSC also found a safety threat to Tread+ users if they lost their balance; and (5) as a result of the foregoing, Defendants' statements about Peloton's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On this news, Peloton's stock price fell $16.28 per share, or more than 14%, over the next three trading days to close at $99.93 per share on April 21, 2021, damaging investors.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Peloton's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/87381

comtex tracking

COMTEX_388203750/2523/2021-06-12T19:21:55

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.